The aim of the present study was to comprehensively assess cytoplasmic and nuclear survivin IHC in prostate cancer in correlation with well-defined clinical and pathological parameters, and to assess the potential of survivin as a prognostic factor in prostate cancer. This evidence concerns the gene BIRC5 and prostate cancer.